DNA strand with stomach silhouette representing gastric cancer research

Gastric Cancer and DNA: Unlocking Targeted Therapies

Nico Varela monogram
Nico Varela in Health & Wellness November 2026 • 4 min read.

"A new review explores how DNA methylation impacts gastric cancer and opens doors to innovative treatment strategies."


Gastric cancer is a formidable health issue worldwide, ranking among the most frequent causes of cancer-related deaths. While genetic factors undoubtedly play a role, a growing body of research highlights the significance of epigenetic alterations, particularly DNA methylation, in the development and progression of this disease.

DNA methylation, a process catalyzed by DNA methyltransferases (DNMTs), is a well-characterized epigenetic hallmark in gastric cancer. Unlike genetic mutations that alter the DNA sequence, epigenetic modifications influence gene expression without changing the underlying code. Understanding these reversible alterations is crucial for developing effective therapeutic strategies.

A recent review delves into the intricate relationship between DNA methylation and gastric cancer. It explores key mechanisms, including the roles of SNPs, infections, and genetic modifications in triggering DNMTs level modification, and their subsequent impact on cancer progression. Crucially, the review focuses on how inhibitors of DNMTs can be strategically employed to combat gastric cancer, especially in cases of multidrug resistance.

AI Search Multiple angles on this topic

Source Limitations

The listed sources do not provide verified statistics about gastric cancer, DNA, or targeted therapies. They instead describe Microsoft Forms, Microsoft Ink Canvas, SQL Server migration, and Windows driver updates. Microsoft Ink Canvas is described as an AI-powered, pen-first experience in a September 21, 2026, Microsoft support entry.

Microsoft Account History

The listed sources do not document historical milestones or foundational discoveries in gastric-cancer genetics. They describe Microsoft products, accounts, subscriptions, and online services instead. Microsoft’s account pages specifically mention access to free online versions of Outlook, Word, Excel, and PowerPoint.

How Does DNA Methylation Go Wrong in Gastric Cancer?

DNA strand with stomach silhouette representing gastric cancer research

Gastric cancer development involves both genetic and epigenetic changes, affecting oncogenes and tumor-suppressor genes (TSGs). While epigenetic modifications are normal during development and tissue differentiation, aberrant epigenetic modifications can disrupt cell function and contribute to cancer. These changes can alter the transcription levels of TSGs and oncogenes without altering DNA sequences.

Epigenetic alterations, including histone modification, noncoding RNA, and DNA methylation, can initiate and sustain changes that inactivate tumor-suppressor genes and other cancer-related genes in gastric cancer. Histone proteins, which determine chromatin structure and function, are modified through acetylation and methylation, affecting gene transcription, DNA replication, and nucleosome positioning.

  • Histone Hyperacetylation: Linked with transcriptional activation.
  • Histone Methylation: The effect depends on the specific amino acid residue modified and the degree of methylation; for example, trimethylation of H3K4 promotes gene expression, while trimethylation of H3K9 and H3K27 suppresses gene expression.
  • miRNAs: Small non-coding RNA molecules, are also key players in epigenetic regulation in gastric cancers. Dysregulation is associated with histone modifications and methylation patterns.
AI Search Multiple angles on this topic

Limited Cancer Research Evidence

The Cancer.gov source reports that the FDA changed its 2021 approval of pembrolizumab, Keytruda, with trastuzumab, Herceptin, and chemotherapy for HER2-positive stomach or gastroesophageal-junction cancer. The other listed sources concern DSW shoes and do not address cancer research. Consequently, the supplied material supports only this specific treatment-regulatory statement.

Biomarker Testing

The Cancer.gov patient information states that a doctor may suggest biomarker tests to help predict a patient’s response to certain targeted therapy drugs. The other listed sources are cat-image websites and provide no evidence about gastric cancer, treatment failures, or targeted-therapy limitations. The supplied material therefore does not support broader conclusions about counterarguments or failures.

Insufficient Comparative Evidence

The listed sources are Japanese-language news landing pages and do not provide a verified comparison of gastric-cancer treatments, DNA alterations, or targeted therapies. Google News displays a weather-related headline about Typhoon 27 and conditions near the Ogasawara Islands on October 3, 2026. Because the sources do not address the requested medical comparison, no evidence-based treatment comparison can be made from them.

DNA methylation, a fundamental epigenetic mechanism, plays a crucial role in maintaining genomic stability through genomic imprinting and X-chromosome inactivation. Aberrant DNA methylation is strongly implicated in the development of various malignancies, including gastric cancer. Factors like age, diet, physical activity, chronic inflammation, and infectious agents can influence DNA methylation patterns in gastric epithelia. Global DNA hypo/hypermethylation commonly occurs in gastric tumors, contributing to genomic instability. Aberrant hyperactivation of DNA methyltransferases (DNMTs) is responsible for silencing or inactivating TSGs, driving cancer development.

The Future of Gastric Cancer Treatment: Targeting DNMTs

Gastric cancer remains a major cause of global morbidity and mortality, with epigenetic disruption playing a crucial role. Emerging evidence highlights the potential of targeting DNMTs to restore normal gene expression and overcome chemoresistance. While general and specific DNMT inhibitors show promise, the development of site-specific silencing strategies using CRISPR-Cas9 technology may offer even more precise and effective therapies for gastric cancer patients.

AI Search Multiple angles on this topic

Unrelated Expert Profiles

The listed sources profile Tarek Saleh, a former Wisconsin football player, rather than a gastric-cancer or genomics expert. The UW Athletic Hall of Fame reports that he was named First-Team All-American in 1996 and Second-Team in 1995 by The Football News. The sources therefore do not support expert commentary on DNA-guided targeted therapies.

How methylation measures compare with treatment outcomes

  • 30%–50% percent response rateFor platinum- and 5-FU-based chemotherapy combinations, the reported response rate was approximately 30%–50%.[1]

What methylation findings can tell us

Methylation-based blood testing had high specificity but lower sensitivity, so its ability to identify cancer was not the same as its ability to rule out cancer in the tested setting.[2]

Methylation can regulate transcription, and cancer involvement has been linked to inappropriate silencing of tumour-suppressor genes or loss of oncogene repression. This describes a possible role in gene regulation, not proof that methylation alone causes a cancer outcome.[3]

How the evidence differs by setting

Models predicting response to anti-PD-1-based treatment performed perfectly on the training set but less strongly on the testing set, a pattern the authors said raised overfitting concerns and limited generalizability.[4]

A retrospective analysis of 56 patients receiving modified FOLFOX was used to assess the prognostic and predictive impact of SULF2 methylation. Its retrospective design describes an evaluation, not prospective confirmation of predictive performance.[1]

Another analysis proposed DNA methylation modules for prognosis after adjuvant chemotherapy while acknowledging a lack of systematic experimental validation. This leaves the proposed clinical role less firmly tested than a validated tool.[5]

What remains unresolved about methylation and resistance

  • How does autophagy activation lead to Linc00942 degradation through p62, and how much does that specific process contribute to chemoresistance in gastric cancer cells?[6]
  • How consistently can the proposed DNA methylation modules predict outcomes when tested with systematic experimental validation?[5]

Terms used in gastric cancer methylation research

DNA methylation
Epigenetic transcriptional regulation[3]
DNMT
DNA methyltransferase[7]

Sources

  1. SULF2 Methylation Is Associated with In Vitro Cisplatin Sensitivity and Clinical Efficacy for Gastric Cancer Patients Treated with a Modified FOLFOX Regimen (pmc.ncbi.nlm.nih.gov)
  2. Diagnostic accuracy of DNA methylation in detection of gastric cancer: a meta-analysis (pmc.ncbi.nlm.nih.gov)
  3. Clinical Potential of DNA Methylation in Gastric Cancer: A Meta-Analysis (pmc.ncbi.nlm.nih.gov)
  4. DNA methylation profiles predicting response to anti-PD-1-based treatment in patients with advanced gastric cancer (pmc.ncbi.nlm.nih.gov)
  5. Predictive value of DNA methylation in the efficacy of chemotherapy for gastric cancer (pmc.ncbi.nlm.nih.gov)
  6. RNautophagic regulation of DNMT3a‐dependent DNA methylation by Linc00942 enhances chemoresistance in gastric cancer (pmc.ncbi.nlm.nih.gov)
  7. Decitabine and Cisplatin are Synergistic to Exert Anti-Tumor Effect on Gastric Cancer via Inducing Sox2 DNA Demethylation (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is DNA methylation, and why is it important in the context of gastric cancer?

DNA methylation is an epigenetic modification where a methyl group is added to a DNA molecule. This process, catalyzed by DNA methyltransferases (DNMTs), doesn't change the DNA sequence itself but can alter gene expression. In the context of gastric cancer, aberrant DNA methylation can lead to the silencing of tumor-suppressor genes (TSGs) or the activation of oncogenes, both of which contribute to cancer development and progression. It is significant because, unlike genetic mutations, DNA methylation is potentially reversible, making it a target for therapeutic intervention. Disruptions in DNA methylation patterns can have profound implications for genomic stability and cellular function, ultimately influencing the development and progression of gastric cancer.

2

What are DNMTs, and why is it important to understand their role in gastric cancer?

DNMTs, or DNA methyltransferases, are enzymes that catalyze the transfer of methyl groups to DNA, specifically to cytosine bases. They are crucial because they mediate DNA methylation, which plays a significant role in gene expression regulation. In gastric cancer, DNMTs are often hyperactivated, leading to abnormal DNA methylation patterns that silence tumor-suppressor genes (TSGs). Targeting DNMTs with inhibitors is a potential therapeutic strategy to restore normal gene expression and combat cancer. The implications of DNMT activity are substantial, as their dysregulation can drive cancer development and influence treatment response.

3

What are epigenetic modifications, and how do they affect gastric cancer?

Epigenetic modifications are changes in gene expression that do not involve alterations to the DNA sequence itself. These modifications, including DNA methylation, histone modification, and noncoding RNAs, are important because they can influence which genes are turned on or off. In gastric cancer, aberrant epigenetic modifications can lead to the silencing of tumor-suppressor genes (TSGs) or the activation of oncogenes, promoting cancer development and progression. These changes are potentially reversible, making them attractive targets for therapeutic intervention. The implications of epigenetic modifications are far-reaching, as they can alter cellular function and contribute to disease development.

4

Why is targeting DNMTs considered a promising approach for treating gastric cancer?

Targeting DNMTs holds promise as a therapeutic strategy for gastric cancer because DNMTs play a crucial role in aberrant DNA methylation, which can silence tumor-suppressor genes (TSGs) and promote cancer development. By inhibiting DNMTs, researchers aim to restore normal gene expression and reverse the epigenetic changes that drive cancer progression. This approach is particularly important in cases of multidrug resistance, where traditional therapies may not be effective. The development of site-specific silencing strategies using technologies like CRISPR-Cas9 may offer even more precise and effective therapies for gastric cancer patients.

5

What are histone modifications and what is their role?

Histone modifications are chemical alterations to histone proteins, which package and organize DNA within the nucleus. These modifications, such as acetylation and methylation, can influence chromatin structure and gene expression. Histone modifications are significant because they play a crucial role in regulating gene transcription, DNA replication, and nucleosome positioning. In gastric cancer, aberrant histone modifications can contribute to the silencing of tumor-suppressor genes (TSGs) or the activation of oncogenes, promoting cancer development and progression. These modifications can lead to changes that inactivate tumor-suppressor genes and other cancer-related genes, and also affect miRNAs, contributing to the disease. Understanding and targeting these modifications may offer new therapeutic avenues for gastric cancer.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.